Mereo BioPharma Group plc (MREO)
MREONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$0.2991
-0.0063 (-2.06%) today
Closed, Nov 11, 4:00 PM ET
- Market cap
- $48.96m
- P/E
- –
- EPS, last 4 quarters
- $-0.0400
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.2000 to $2.37
- Average volume
- –
- Previous close
- $0.3054
Analysts
4 coveringHold2 buy, 1 hold, 1 sell
Targets a year out average $2.00, +568.7% from here
Earnings
next estimate $-0.0100Next report
Dec 2025
0.0%
Mar 2026
-150.0%
Jun 2026
0.0%
Sep 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | $800.0k |
| Gross profit | – | – | – | $800.0k |
| Operating income | -$8.39m | -$8.77m | -$7.03m | -$6.22m |
| Net income | -$7.35m | -$6.72m | -$7.00m | -$5.86m |
News
8 latest- Mereo BioPharma Group plc Reports Third Quarter 2026 Financial ResultsFintel · 2 days ago
- Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals RTTNews · Aug 15, 2026
- Mereo BioPharma Advances Alvelestat Partnership; Cash Runway Extended Into Late 2027 RTTNews · Aug 11, 2026
- Mereo BioPharma Licenses Alvelestat Rights To Sentynl Therapeutics RTTNews · Aug 11, 2026
- Mereo BioPharma Assessing A Potential Path Forward For Setrusumab In Brittle Bone Disease? RTTNews · Jan 14, 2026
- RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary EndpointZacks · Dec 30, 2025
- Needham Reiterates Mereo BioPharma Group plc - Depositary Receipt (MREO) Buy RecommendationFintel · Dec 22, 2025
- BTIG Reiterates Mereo BioPharma Group plc - Depositary Receipt (MREO) Buy RecommendationFintel · Dec 18, 2025
The company
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has three rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); alvelestat for the treatment of alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD); and vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2). The Company seeks to combine partnerships that provide validation for its programs and non-dilutive capital to fund late-stage clinical development, with the upside of retaining commercial rights in key strategic territories, including Europe. The Company and its partner for setrusumab, Ultragenyx Pharmaceutical Inc., have reported top-line results from two Phase 3 studies for setrusumab in OI in patients aged 2 to 25 years old. Ultragenyx is funding and leading global development and Mereo has retained EU and UK commercial rights.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- mereobiopharma.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.